ART and prevention of HIV-associated tuberculosis
- 1 June 2015
- journal article
- editorial
- Published by Elsevier in The Lancet HIV
- Vol. 2 (6) , e221-e222
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Does antiretroviral therapy reduce HIV-associated tuberculosis incidence to background rates? A national observational cohort study from England, Wales, and Northern IrelandThe Lancet HIV, 2015
- Decline in national tuberculosis notifications with national scale-up of antiretroviral therapy in MalawiPublic Health Action, 2014
- Antiretroviral Therapy for Prevention of Tuberculosis in Adults with HIV: A Systematic Review and Meta-AnalysisPLOS Medicine, 2012
- Tuberculosis Incidence Rates during 8 Years of Follow-Up of an Antiretroviral Treatment Cohort in South Africa: Comparison with Rates in the CommunityPLOS ONE, 2012
- Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it? [Unresolved issues]The International Journal of Tuberculosis and Lung Disease, 2011
- Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resourcesThe Lancet Infectious Diseases, 2010
- Antiretroviral Therapy for Control of the HIV-associated Tuberculosis Epidemic in Resource-Limited SettingsClinics in Chest Medicine, 2009
- Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis controlAIDS, 2006
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Distribution of CD4+ T Lymphocytes at Diagnosis of Acquired Immunodeficiency Syndrome—Defining and Other Human Immunodeficiency Virus—Related IllnessesArchives of internal medicine (1960), 1995